SCHEMBL160142

SCHEMBL160142

O=C(Nc1ccncc1)c1ccccc1N1CCN(C(=O)CN2C(=O)c3ccccc3S2(=O)=O)CC1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.63
SMN1; SMN2 Q16637 4/20 0.59
RAB9A P51151 7/20 0.55
NPC1 O15118 6/20 0.55
TSHR P16473 1/20 0.53
MAPK1 P28482 1/20 0.53
CYP2C19 P33261 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
MAPT P10636 2/20 0.48
TP53 P04637 1/20 0.48
HSP90AA1 P07900 1/20 0.48
PAX8 Q06710 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
LMNA P02545 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
HTT P42858 1/20 0.47
ATM Q13315 1/20 0.46
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3101690 0.84 HSD17B10 (0.55) ALDH1A1SMN1; SMN2TSHRMAPTL3MBTL1
SCHEMBL3105176 0.80 RAB9A (0.43) ALDH1A1SMN1; SMN2RAB9AL3MBTL1LMNA
SCHEMBL163235 0.79 HSD17B10 (0.45) ALDH1A1SMN1; SMN2TSHRMAPTL3MBTL1
SCHEMBL113050 0.78 TRPV1 (0.44) ALDH1A1SMN1; SMN2MAPK1LMNAHTT
SCHEMBL3105119 0.77 TRPV1 (0.50) ALDH1A1SMN1; SMN2HTTKMT2A
SCHEMBL111886 0.77 ADRA1D (0.44) SMN1; SMN2HTT
SCHEMBL111730 0.75 GAA (0.57) ALDH1A1SMN1; SMN2RAB9ANPC1TDP1
SCHEMBL111857 0.75 TRPV1 (0.47) ALDH1A1SMN1; SMN2RAB9AMAPTHTT
SCHEMBL162320 0.75 CXCR3 (0.51) ALDH1A1SMN1; SMN2TP53LMNAHTT
SCHEMBL110281 0.74 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2NPC1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424858-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-05-14 EP disclosed
EP-2424858-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-05-14 EP disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
EP-2424858-A1 CXCR3 RECEPTOR ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-03-07 EP disclosed
WO-2010126851-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
WO-2010126851-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 ALDH1A1 1720/4885SMN1; SMN2 4561/4885RAB9A 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.